Risk Factors and Outcomes for Patients with Bloodstream Infection Due to Acinetobacter baumannii-calcoaceticus Complex
Identifying patients at risk for bloodstream infection (BSI) due to Acinetobacter baumannii-Acinetobacter calcoaceticus complex (ABC) and providing early appropriate therapy are critical for improving patient outcomes. A retrospective matched case-control study was conducted to investigate the risk...
Gespeichert in:
Veröffentlicht in: | Antimicrobial agents and chemotherapy 2014-08, Vol.58 (8), p.4630-4635 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 4635 |
---|---|
container_issue | 8 |
container_start_page | 4630 |
container_title | Antimicrobial agents and chemotherapy |
container_volume | 58 |
creator | CHOPRA, Teena MARCHAIM, Dror KAYE, Keith S JOHNSON, Paul C AWALI, Reda A DOSHI, Hardik CHALANA, Indu DAVIS, Naomi ZHAO, Jing J POGUE, Jason M PARMAR, Sapna |
description | Identifying patients at risk for bloodstream infection (BSI) due to Acinetobacter baumannii-Acinetobacter calcoaceticus complex (ABC) and providing early appropriate therapy are critical for improving patient outcomes. A retrospective matched case-control study was conducted to investigate the risk factors for BSI due to ABC in patients admitted to the Detroit Medical Center (DMC) between January 2006 and April 2009. The cases were patients with BSI due to ABC; the controls were patients not infected with ABC. Potential risk factors were collected 30 days prior to the ABC-positive culture date for the cases and 30 days prior to admission for the controls. A total of 245 case patients were matched with 245 control patients. Independent risk factors associated with BSI due to ABC included a Charlson's comorbidity score of ≥ 3 (odds ratio [OR], 2.34; P = 0.001), a direct admission from another health care facility (OR, 4.63; P < 0.0001), a prior hospitalization (OR, 3.11; P < 0.0001), the presence of an indwelling central venous line (OR, 2.75; P = 0.011), the receipt of total parenteral nutrition (OR, 21.2; P < 0.0001), the prior receipt of β-lactams (OR, 3.58; P < 0.0001), the prior receipt of carbapenems (OR, 3.18; P = 0.006), and the prior receipt of chemotherapy (OR, 15.42; P < 0.0001). The median time from the ABC-positive culture date to the initiation of the appropriate antimicrobial therapy was 2 days (interquartile range [IQR], 1 to 3 days). The in-hospital mortality rate was significantly higher among case patients than among control patients (OR, 3.40; P < 0.0001). BSIs due to ABC are more common among critically ill and debilitated institutionalized patients, who are heavily exposed to health care settings and invasive devices. |
doi_str_mv | 10.1128/AAC.02441-14 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4135982</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1560109898</sourcerecordid><originalsourceid>FETCH-LOGICAL-a524t-2e7cb83587f848870dfc878baac183e1da3d728c1882fe7cab084b3a1b892c2a3</originalsourceid><addsrcrecordid>eNp1kUFv1DAQRi0Eokvhxhn5ggQSKbbjJOML0rKlUKlSEYKzNXEc6pLYW9sp8O_rskuBAydr5Kc3mu8j5ClnR5wLeL1eb46YkJJXXN4jK84UVG2j2vtkxVjbVhKYPCCPUrpkZW4Ue0gOhATFGiVX5PqTS9_oCZocYqLoB3q-ZBNmm-gYIv2I2VmfE_3u8gV9O4UwpBwtzvTUj9ZkFzw9XizNga6N8zaHvqhspD0uM3rvXGVwMgGNzc4siW7CvJ3sj8fkwYhTsk_27yH5cvLu8-ZDdXb-_nSzPquwETJXwnamh7qBbgQJ0LFhNNBBj2g41JYPWA-dgDKAGAuLPQPZ18h7UMIIrA_Jm513u_SzHUy5JeKkt9HNGH_qgE7_--Pdhf4arrXkdaNAFMGLvSCGq8WmrGeXjJ0m9DYsSfOmZbeRKyjoqx1qYkgp2vFuDWf6tipdqtK_qtJcFvzlDsc0C30ZluhLEv9jn_19xp34d48FeL4HMJXAx4jeuPSHg1Zx6GR9A5isqzY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1560109898</pqid></control><display><type>article</type><title>Risk Factors and Outcomes for Patients with Bloodstream Infection Due to Acinetobacter baumannii-calcoaceticus Complex</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>CHOPRA, Teena ; MARCHAIM, Dror ; KAYE, Keith S ; JOHNSON, Paul C ; AWALI, Reda A ; DOSHI, Hardik ; CHALANA, Indu ; DAVIS, Naomi ; ZHAO, Jing J ; POGUE, Jason M ; PARMAR, Sapna</creator><creatorcontrib>CHOPRA, Teena ; MARCHAIM, Dror ; KAYE, Keith S ; JOHNSON, Paul C ; AWALI, Reda A ; DOSHI, Hardik ; CHALANA, Indu ; DAVIS, Naomi ; ZHAO, Jing J ; POGUE, Jason M ; PARMAR, Sapna</creatorcontrib><description><![CDATA[Identifying patients at risk for bloodstream infection (BSI) due to Acinetobacter baumannii-Acinetobacter calcoaceticus complex (ABC) and providing early appropriate therapy are critical for improving patient outcomes. A retrospective matched case-control study was conducted to investigate the risk factors for BSI due to ABC in patients admitted to the Detroit Medical Center (DMC) between January 2006 and April 2009. The cases were patients with BSI due to ABC; the controls were patients not infected with ABC. Potential risk factors were collected 30 days prior to the ABC-positive culture date for the cases and 30 days prior to admission for the controls. A total of 245 case patients were matched with 245 control patients. Independent risk factors associated with BSI due to ABC included a Charlson's comorbidity score of ≥ 3 (odds ratio [OR], 2.34; P = 0.001), a direct admission from another health care facility (OR, 4.63; P < 0.0001), a prior hospitalization (OR, 3.11; P < 0.0001), the presence of an indwelling central venous line (OR, 2.75; P = 0.011), the receipt of total parenteral nutrition (OR, 21.2; P < 0.0001), the prior receipt of β-lactams (OR, 3.58; P < 0.0001), the prior receipt of carbapenems (OR, 3.18; P = 0.006), and the prior receipt of chemotherapy (OR, 15.42; P < 0.0001). The median time from the ABC-positive culture date to the initiation of the appropriate antimicrobial therapy was 2 days (interquartile range [IQR], 1 to 3 days). The in-hospital mortality rate was significantly higher among case patients than among control patients (OR, 3.40; P < 0.0001). BSIs due to ABC are more common among critically ill and debilitated institutionalized patients, who are heavily exposed to health care settings and invasive devices.]]></description><identifier>ISSN: 0066-4804</identifier><identifier>EISSN: 1098-6596</identifier><identifier>DOI: 10.1128/AAC.02441-14</identifier><identifier>PMID: 24890594</identifier><identifier>CODEN: AACHAX</identifier><language>eng</language><publisher>Washington, DC: American Society for Microbiology</publisher><subject>Acinetobacter ; Acinetobacter baumannii ; Acinetobacter baumannii - drug effects ; Acinetobacter baumannii - pathogenicity ; Acinetobacter baumannii - physiology ; Acinetobacter calcoaceticus ; Acinetobacter calcoaceticus - drug effects ; Acinetobacter calcoaceticus - pathogenicity ; Acinetobacter calcoaceticus - physiology ; Acinetobacter Infections ; Acinetobacter Infections - drug therapy ; Acinetobacter Infections - etiology ; Acinetobacter Infections - microbiology ; Acinetobacter Infections - mortality ; Adult ; Aged ; Anti-Bacterial Agents - adverse effects ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antineoplastic Agents - adverse effects ; Bacteremia ; Bacteremia - drug therapy ; Bacteremia - etiology ; Bacteremia - microbiology ; Bacteremia - mortality ; Bacterial diseases ; Bacterial sepsis ; Biological and medical sciences ; Case-Control Studies ; Catheters, Indwelling - adverse effects ; Epidemiology and Surveillance ; Female ; Hospital Mortality ; Hospitalization - statistics & numerical data ; Human bacterial diseases ; Humans ; Infectious diseases ; Male ; Medical sciences ; Middle Aged ; Parenteral Nutrition - adverse effects ; Pharmacology. Drug treatments ; Retrospective Studies ; Risk Factors ; Survival Analysis</subject><ispartof>Antimicrobial agents and chemotherapy, 2014-08, Vol.58 (8), p.4630-4635</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</rights><rights>Copyright © 2014, American Society for Microbiology. All Rights Reserved. 2014 American Society for Microbiology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a524t-2e7cb83587f848870dfc878baac183e1da3d728c1882fe7cab084b3a1b892c2a3</citedby><cites>FETCH-LOGICAL-a524t-2e7cb83587f848870dfc878baac183e1da3d728c1882fe7cab084b3a1b892c2a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135982/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135982/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28691874$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24890594$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CHOPRA, Teena</creatorcontrib><creatorcontrib>MARCHAIM, Dror</creatorcontrib><creatorcontrib>KAYE, Keith S</creatorcontrib><creatorcontrib>JOHNSON, Paul C</creatorcontrib><creatorcontrib>AWALI, Reda A</creatorcontrib><creatorcontrib>DOSHI, Hardik</creatorcontrib><creatorcontrib>CHALANA, Indu</creatorcontrib><creatorcontrib>DAVIS, Naomi</creatorcontrib><creatorcontrib>ZHAO, Jing J</creatorcontrib><creatorcontrib>POGUE, Jason M</creatorcontrib><creatorcontrib>PARMAR, Sapna</creatorcontrib><title>Risk Factors and Outcomes for Patients with Bloodstream Infection Due to Acinetobacter baumannii-calcoaceticus Complex</title><title>Antimicrobial agents and chemotherapy</title><addtitle>Antimicrob Agents Chemother</addtitle><addtitle>Antimicrob Agents Chemother</addtitle><description><![CDATA[Identifying patients at risk for bloodstream infection (BSI) due to Acinetobacter baumannii-Acinetobacter calcoaceticus complex (ABC) and providing early appropriate therapy are critical for improving patient outcomes. A retrospective matched case-control study was conducted to investigate the risk factors for BSI due to ABC in patients admitted to the Detroit Medical Center (DMC) between January 2006 and April 2009. The cases were patients with BSI due to ABC; the controls were patients not infected with ABC. Potential risk factors were collected 30 days prior to the ABC-positive culture date for the cases and 30 days prior to admission for the controls. A total of 245 case patients were matched with 245 control patients. Independent risk factors associated with BSI due to ABC included a Charlson's comorbidity score of ≥ 3 (odds ratio [OR], 2.34; P = 0.001), a direct admission from another health care facility (OR, 4.63; P < 0.0001), a prior hospitalization (OR, 3.11; P < 0.0001), the presence of an indwelling central venous line (OR, 2.75; P = 0.011), the receipt of total parenteral nutrition (OR, 21.2; P < 0.0001), the prior receipt of β-lactams (OR, 3.58; P < 0.0001), the prior receipt of carbapenems (OR, 3.18; P = 0.006), and the prior receipt of chemotherapy (OR, 15.42; P < 0.0001). The median time from the ABC-positive culture date to the initiation of the appropriate antimicrobial therapy was 2 days (interquartile range [IQR], 1 to 3 days). The in-hospital mortality rate was significantly higher among case patients than among control patients (OR, 3.40; P < 0.0001). BSIs due to ABC are more common among critically ill and debilitated institutionalized patients, who are heavily exposed to health care settings and invasive devices.]]></description><subject>Acinetobacter</subject><subject>Acinetobacter baumannii</subject><subject>Acinetobacter baumannii - drug effects</subject><subject>Acinetobacter baumannii - pathogenicity</subject><subject>Acinetobacter baumannii - physiology</subject><subject>Acinetobacter calcoaceticus</subject><subject>Acinetobacter calcoaceticus - drug effects</subject><subject>Acinetobacter calcoaceticus - pathogenicity</subject><subject>Acinetobacter calcoaceticus - physiology</subject><subject>Acinetobacter Infections</subject><subject>Acinetobacter Infections - drug therapy</subject><subject>Acinetobacter Infections - etiology</subject><subject>Acinetobacter Infections - microbiology</subject><subject>Acinetobacter Infections - mortality</subject><subject>Adult</subject><subject>Aged</subject><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Bacteremia</subject><subject>Bacteremia - drug therapy</subject><subject>Bacteremia - etiology</subject><subject>Bacteremia - microbiology</subject><subject>Bacteremia - mortality</subject><subject>Bacterial diseases</subject><subject>Bacterial sepsis</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>Catheters, Indwelling - adverse effects</subject><subject>Epidemiology and Surveillance</subject><subject>Female</subject><subject>Hospital Mortality</subject><subject>Hospitalization - statistics & numerical data</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Parenteral Nutrition - adverse effects</subject><subject>Pharmacology. Drug treatments</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Survival Analysis</subject><issn>0066-4804</issn><issn>1098-6596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUFv1DAQRi0Eokvhxhn5ggQSKbbjJOML0rKlUKlSEYKzNXEc6pLYW9sp8O_rskuBAydr5Kc3mu8j5ClnR5wLeL1eb46YkJJXXN4jK84UVG2j2vtkxVjbVhKYPCCPUrpkZW4Ue0gOhATFGiVX5PqTS9_oCZocYqLoB3q-ZBNmm-gYIv2I2VmfE_3u8gV9O4UwpBwtzvTUj9ZkFzw9XizNga6N8zaHvqhspD0uM3rvXGVwMgGNzc4siW7CvJ3sj8fkwYhTsk_27yH5cvLu8-ZDdXb-_nSzPquwETJXwnamh7qBbgQJ0LFhNNBBj2g41JYPWA-dgDKAGAuLPQPZ18h7UMIIrA_Jm513u_SzHUy5JeKkt9HNGH_qgE7_--Pdhf4arrXkdaNAFMGLvSCGq8WmrGeXjJ0m9DYsSfOmZbeRKyjoqx1qYkgp2vFuDWf6tipdqtK_qtJcFvzlDsc0C30ZluhLEv9jn_19xp34d48FeL4HMJXAx4jeuPSHg1Zx6GR9A5isqzY</recordid><startdate>20140801</startdate><enddate>20140801</enddate><creator>CHOPRA, Teena</creator><creator>MARCHAIM, Dror</creator><creator>KAYE, Keith S</creator><creator>JOHNSON, Paul C</creator><creator>AWALI, Reda A</creator><creator>DOSHI, Hardik</creator><creator>CHALANA, Indu</creator><creator>DAVIS, Naomi</creator><creator>ZHAO, Jing J</creator><creator>POGUE, Jason M</creator><creator>PARMAR, Sapna</creator><general>American Society for Microbiology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20140801</creationdate><title>Risk Factors and Outcomes for Patients with Bloodstream Infection Due to Acinetobacter baumannii-calcoaceticus Complex</title><author>CHOPRA, Teena ; MARCHAIM, Dror ; KAYE, Keith S ; JOHNSON, Paul C ; AWALI, Reda A ; DOSHI, Hardik ; CHALANA, Indu ; DAVIS, Naomi ; ZHAO, Jing J ; POGUE, Jason M ; PARMAR, Sapna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a524t-2e7cb83587f848870dfc878baac183e1da3d728c1882fe7cab084b3a1b892c2a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Acinetobacter</topic><topic>Acinetobacter baumannii</topic><topic>Acinetobacter baumannii - drug effects</topic><topic>Acinetobacter baumannii - pathogenicity</topic><topic>Acinetobacter baumannii - physiology</topic><topic>Acinetobacter calcoaceticus</topic><topic>Acinetobacter calcoaceticus - drug effects</topic><topic>Acinetobacter calcoaceticus - pathogenicity</topic><topic>Acinetobacter calcoaceticus - physiology</topic><topic>Acinetobacter Infections</topic><topic>Acinetobacter Infections - drug therapy</topic><topic>Acinetobacter Infections - etiology</topic><topic>Acinetobacter Infections - microbiology</topic><topic>Acinetobacter Infections - mortality</topic><topic>Adult</topic><topic>Aged</topic><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Bacteremia</topic><topic>Bacteremia - drug therapy</topic><topic>Bacteremia - etiology</topic><topic>Bacteremia - microbiology</topic><topic>Bacteremia - mortality</topic><topic>Bacterial diseases</topic><topic>Bacterial sepsis</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>Catheters, Indwelling - adverse effects</topic><topic>Epidemiology and Surveillance</topic><topic>Female</topic><topic>Hospital Mortality</topic><topic>Hospitalization - statistics & numerical data</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Parenteral Nutrition - adverse effects</topic><topic>Pharmacology. Drug treatments</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Survival Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CHOPRA, Teena</creatorcontrib><creatorcontrib>MARCHAIM, Dror</creatorcontrib><creatorcontrib>KAYE, Keith S</creatorcontrib><creatorcontrib>JOHNSON, Paul C</creatorcontrib><creatorcontrib>AWALI, Reda A</creatorcontrib><creatorcontrib>DOSHI, Hardik</creatorcontrib><creatorcontrib>CHALANA, Indu</creatorcontrib><creatorcontrib>DAVIS, Naomi</creatorcontrib><creatorcontrib>ZHAO, Jing J</creatorcontrib><creatorcontrib>POGUE, Jason M</creatorcontrib><creatorcontrib>PARMAR, Sapna</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Antimicrobial agents and chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CHOPRA, Teena</au><au>MARCHAIM, Dror</au><au>KAYE, Keith S</au><au>JOHNSON, Paul C</au><au>AWALI, Reda A</au><au>DOSHI, Hardik</au><au>CHALANA, Indu</au><au>DAVIS, Naomi</au><au>ZHAO, Jing J</au><au>POGUE, Jason M</au><au>PARMAR, Sapna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk Factors and Outcomes for Patients with Bloodstream Infection Due to Acinetobacter baumannii-calcoaceticus Complex</atitle><jtitle>Antimicrobial agents and chemotherapy</jtitle><stitle>Antimicrob Agents Chemother</stitle><addtitle>Antimicrob Agents Chemother</addtitle><date>2014-08-01</date><risdate>2014</risdate><volume>58</volume><issue>8</issue><spage>4630</spage><epage>4635</epage><pages>4630-4635</pages><issn>0066-4804</issn><eissn>1098-6596</eissn><coden>AACHAX</coden><abstract><![CDATA[Identifying patients at risk for bloodstream infection (BSI) due to Acinetobacter baumannii-Acinetobacter calcoaceticus complex (ABC) and providing early appropriate therapy are critical for improving patient outcomes. A retrospective matched case-control study was conducted to investigate the risk factors for BSI due to ABC in patients admitted to the Detroit Medical Center (DMC) between January 2006 and April 2009. The cases were patients with BSI due to ABC; the controls were patients not infected with ABC. Potential risk factors were collected 30 days prior to the ABC-positive culture date for the cases and 30 days prior to admission for the controls. A total of 245 case patients were matched with 245 control patients. Independent risk factors associated with BSI due to ABC included a Charlson's comorbidity score of ≥ 3 (odds ratio [OR], 2.34; P = 0.001), a direct admission from another health care facility (OR, 4.63; P < 0.0001), a prior hospitalization (OR, 3.11; P < 0.0001), the presence of an indwelling central venous line (OR, 2.75; P = 0.011), the receipt of total parenteral nutrition (OR, 21.2; P < 0.0001), the prior receipt of β-lactams (OR, 3.58; P < 0.0001), the prior receipt of carbapenems (OR, 3.18; P = 0.006), and the prior receipt of chemotherapy (OR, 15.42; P < 0.0001). The median time from the ABC-positive culture date to the initiation of the appropriate antimicrobial therapy was 2 days (interquartile range [IQR], 1 to 3 days). The in-hospital mortality rate was significantly higher among case patients than among control patients (OR, 3.40; P < 0.0001). BSIs due to ABC are more common among critically ill and debilitated institutionalized patients, who are heavily exposed to health care settings and invasive devices.]]></abstract><cop>Washington, DC</cop><pub>American Society for Microbiology</pub><pmid>24890594</pmid><doi>10.1128/AAC.02441-14</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0066-4804 |
ispartof | Antimicrobial agents and chemotherapy, 2014-08, Vol.58 (8), p.4630-4635 |
issn | 0066-4804 1098-6596 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4135982 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
subjects | Acinetobacter Acinetobacter baumannii Acinetobacter baumannii - drug effects Acinetobacter baumannii - pathogenicity Acinetobacter baumannii - physiology Acinetobacter calcoaceticus Acinetobacter calcoaceticus - drug effects Acinetobacter calcoaceticus - pathogenicity Acinetobacter calcoaceticus - physiology Acinetobacter Infections Acinetobacter Infections - drug therapy Acinetobacter Infections - etiology Acinetobacter Infections - microbiology Acinetobacter Infections - mortality Adult Aged Anti-Bacterial Agents - adverse effects Antibiotics. Antiinfectious agents. Antiparasitic agents Antineoplastic Agents - adverse effects Bacteremia Bacteremia - drug therapy Bacteremia - etiology Bacteremia - microbiology Bacteremia - mortality Bacterial diseases Bacterial sepsis Biological and medical sciences Case-Control Studies Catheters, Indwelling - adverse effects Epidemiology and Surveillance Female Hospital Mortality Hospitalization - statistics & numerical data Human bacterial diseases Humans Infectious diseases Male Medical sciences Middle Aged Parenteral Nutrition - adverse effects Pharmacology. Drug treatments Retrospective Studies Risk Factors Survival Analysis |
title | Risk Factors and Outcomes for Patients with Bloodstream Infection Due to Acinetobacter baumannii-calcoaceticus Complex |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T21%3A55%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20Factors%20and%20Outcomes%20for%20Patients%20with%20Bloodstream%20Infection%20Due%20to%20Acinetobacter%20baumannii-calcoaceticus%20Complex&rft.jtitle=Antimicrobial%20agents%20and%20chemotherapy&rft.au=CHOPRA,%20Teena&rft.date=2014-08-01&rft.volume=58&rft.issue=8&rft.spage=4630&rft.epage=4635&rft.pages=4630-4635&rft.issn=0066-4804&rft.eissn=1098-6596&rft.coden=AACHAX&rft_id=info:doi/10.1128/AAC.02441-14&rft_dat=%3Cproquest_pubme%3E1560109898%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1560109898&rft_id=info:pmid/24890594&rfr_iscdi=true |